Management of side effects of mTOR inhibitors in tuberous sclerosis patients
K Sadowski, K Kotulska, S Jóźwiak - Pharmacological Reports, 2016 - Springer
K Sadowski, K Kotulska, S Jóźwiak
Pharmacological Reports, 2016•SpringerAbstract mTOR inhibitors represent a relatively new therapeutic option in the management of
patients affected by tuberous sclerosis complex (TSC). Randomized clinical trials support
the use of everolimus in the treatment of subependymal giant cell astrocytomas (SEGA) and
renal angiomyolipomas (AML) related to TSC. Accumulating data suggest also systemic
disease-modifying potential of mTOR inhibitors. Given that increasing number of patients
with TSC receive mTOR inhibitors, the issue of adverse events associated with this therapy …
patients affected by tuberous sclerosis complex (TSC). Randomized clinical trials support
the use of everolimus in the treatment of subependymal giant cell astrocytomas (SEGA) and
renal angiomyolipomas (AML) related to TSC. Accumulating data suggest also systemic
disease-modifying potential of mTOR inhibitors. Given that increasing number of patients
with TSC receive mTOR inhibitors, the issue of adverse events associated with this therapy …
Abstract
mTOR inhibitors represent a relatively new therapeutic option in the management of patients affected by tuberous sclerosis complex (TSC). Randomized clinical trials support the use of everolimus in the treatment of subependymal giant cell astrocytomas (SEGA) and renal angiomyolipomas (AML) related to TSC. Accumulating data suggest also systemic disease-modifying potential of mTOR inhibitors.
Given that increasing number of patients with TSC receive mTOR inhibitors, the issue of adverse events associated with this therapy becomes practically important. In the present study we provide the overview of clinical manifestations and therapeutic options for the most common adverse events related to mTOR inhibitors in TSC patients.
Springer
